Inhalable Dry Powders for Lung mRNA Delivery
Advanced Healthcare Materials · 2024-11 · 13 (29)
DOI: 10.1002/adhm.202400509 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 01.10.2024. Verfasst von Akiva Gordon und 4 weiteren Autor:innen. Beteiligte Einrichtung: David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. Hauptthemen laut MEDLINE: Powders, Lung, RNA, Messenger. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cystic Fibrosis Foundation, NIAID NIH HHS.
Abstract (Originalsprache)
Despite great promise, application of mRNA therapeutics in the lung has proven challenging. Many groups have reported success instilling liquid mRNA formulations in animal models, but direct intratracheal administration of large liquid quantities to the human lung presents significant safety and distribution concerns. To accomplish safe and effective mRNA delivery to the lung, formulations must be prepared for dosing via inhalation. An inhaled mRNA delivery system for the lung must be both robust enough to survive inhalation conditions and potent enough to deliver mRNA upon reaching the lung. In this work dry powder lipid nanoparticle formulations are developed, using spray‐freeze‐drying, to produce stable, biologically active, inhalable dry powders for mRNA delivery. The final powders have suitable aerosolization properties, with mean mass aerodynamic diameter (MMAD) of 3–4 microns, and fine particle fraction (FPF) ≈40%, allowing for efficient mRNA delivery to the deep lung following inhalation. Importantly, the formulations developed here are suitable for use with different ionizable lipids. Four different ionizable lipid‐based formulations are evaluated as powders, and all exhibit in vivo pulmonary mRNA delivery equal to that of instilled liquid formulations. These results lay promising groundwork for the eventual development of an inhalable mRNA dry powder therapeutic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
- Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.
- Department of Chemistry, University of Toronto, Toronto, Ontario, Canada.
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
ORCID-Profile: Akiva Gordon, Jacob Witten, Daniel G Anderson
Förderung
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Cystic Fibrosis Foundation
- NIAID NIH HHS
- Alpha-1 Foundation
- NIH HHS
- Sanofi
- NHLBI NIH HHS
- NCI NIH HHS
Zitieren
APA
Gordon, A., Li, B., Witten, J., Nguyen, H., & Anderson, D. G. (2024). Inhalable Dry Powders for Lung mRNA Delivery. Advanced Healthcare Materials, 13(29). https://doi.org/10.1002/adhm.202400509
Vancouver
Gordon A, Li B, Witten J, Nguyen H, Anderson DG. Inhalable Dry Powders for Lung mRNA Delivery. Advanced Healthcare Materials. 2024;13(29). doi:10.1002/adhm.202400509
BibTeX
@article{Gordon2024,
author = {Gordon, Akiva and Li, Bowen and Witten, Jacob and Nguyen, Hong and Anderson, Daniel G},
title = {Inhalable Dry Powders for Lung mRNA Delivery},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {29},
doi = {10.1002/adhm.202400509}
}
EUVIMED